FGFR2 and bladder transitional cell carcinoma: Erdafitinib, type I1/2A pan-FGFR inhibitor, is FDA-approved for treating locally-advanced, unresectable, or metastatic urothelial carcinoma that has progressed during or after platinum-based chemotherapy and as first-line treatment of urothelial bladder cancer exhibiting FGFR2 or 3 mutations [39].